Heng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heng Li has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Yang Luo
Kunming Medical University
3 shared publications - Baolan Lu
Department of Radiology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
1 shared publication - Bin Zhao
School of Environment, Hangzhou Institute for Advanced Study
1 shared publication - Chao-Ke Tang
Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, 2020 Grade Excellent Doctor Class of Hengyang Medical College, University of South China, Hengyang, Hunan 421001, China
1 shared publication Chaoke Tang
Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, Hengyang Medical School, University of South China Hengyang Hunan China
1 shared publication- Chengyi Hou
State Key Laboratory For Advanced Fiber Materials College of Materials Science and Engineering Donghua University Shanghai P. R. China
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 13 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 271
Tumor heterogeneity: development, mechanisms, and therapeutic implications
Tumor heterogeneity is a fundamental hallmark of cancer that drives progression, metastasis and therapeutic resistance. This diversity originates from persistent genomic instability, dynamic clonal evolution, and cancer stem cell plasticity, which are further amplified through complex crosstalk within the tumor microenvironment. While conventional therapies effectively eliminate certain tumor cell populations, residual resistant subclones frequently lead to disease relapse. Recent breakthroughs in single-cell multi-omics, spatial transcriptomics, and liquid biopsy now enable a comprehensive, multidimensional dissection of tumor heterogeneity across molecular, cellular, spatial, and temporal scales. These approaches reveal real-time dynamics of tumor evolution, providing new opportunities for therapeutic intervention. This review synthesizes key advances in understanding tumor heterogeneity: from its cellular origins and molecular mechanisms to its multidimensional manifestation in the tumor microenvironment and from metastatic heterogeneity to the fundamental causes of treatment resistance. We critically examine how these insights are informing novel therapeutic paradigms—including targeting clonal cooperative networks, modulating epigenetic plasticity and reprogramming metabolic adaptations. Finally, we outline future pathways toward precision medicine through the integration of multi-omics data and dynamic monitoring technologies. Ultimately, overcoming tumor heterogeneity necessitates reconceptualizing cancer not as a static collection of cells but as a dynamically evolving ecosystem.
- 13 July 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1) , 271
Top Cited PapersOpen AccessTumor heterogeneity: development, mechanisms, and therapeutic implications
Tumor heterogeneity is a fundamental hallmark of cancer that drives progression, metastasis and therapeutic resistance. This diversity originates from persistent genomic instability, dynamic clonal evolution, and cancer stem cell plasticity, which are further amplified through complex crosstalk within the tumor microenvironment. While conventional therapies effectively eliminate certain tumor cell populations, residual resistant subclones frequently lead to disease relapse. Recent breakthroughs in single-cell multi-omics, spatial transcriptomics, and liquid biopsy now enable a comprehensive, multidimensional dissection of tumor heterogeneity across molecular, cellular, spatial, and temporal scales. These approaches reveal real-time dynamics of tumor evolution, providing new opportunities for therapeutic intervention. This review synthesizes key advances in understanding tumor heterogeneity: from its cellular origins and molecular mechanisms to its multidimensional manifestation in the tumor microenvironment and from metastatic heterogeneity to the fundamental causes of treatment resistance. We critically examine how these insights are informing novel therapeutic paradigms—including targeting clonal cooperative networks, modulating epigenetic plasticity and reprogramming metabolic adaptations. Finally, we outline future pathways toward precision medicine through the integration of multi-omics data and dynamic monitoring technologies. Ultimately, overcoming tumor heterogeneity necessitates reconceptualizing cancer not as a static collection of cells but as a dynamically evolving ecosystem.
- Open Access
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed7719
High-fidelity molecular decoding through tile-guided in situ self-assembly
High-fidelity profiling of intracellular biomarkers is crucial for deciphering tumorigenesis and progression, as well as classifying cell types. Conventional techniques suffer from high background interference and poor stability due to the scattered, point-like signals. Herein, we present a DNA tile–driven in vivo logical encoding self-assembly (TILES) strategy for robust and signal-amplified imaging of multiple biomarkers in cancer cells and tumor-bearing mice. Capitalizing on AND-gated logic operations, the TILES assay enables confined recognition of dual biomarkers to initiate the intracellular self-assembly of DNA scaffolds, yielding nanotube-like signals. Owing to the compact nucleic acid framework, DNA scaffolds exhibit an over sevenfold nuclease resistance enhancement than double-stranded DNA probes. Moreover, the structural output, characterized by high-density fluorophore architecture and defined morphology, substantially boosts the visualization and precise classification of diverse cancer types. The proposed strategy provides a robust platform to enable the high-fidelity, multiplexed profiling of intracellular biomarkers and dynamic gene regulatory networks analysis in living organisms.
- 22 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (21) , eaed7719
Open AccessHigh-fidelity molecular decoding through tile-guided in situ self-assembly
High-fidelity profiling of intracellular biomarkers is crucial for deciphering tumorigenesis and progression, as well as classifying cell types. Conventional techniques suffer from high background interference and poor stability due to the scattered, point-like signals. Herein, we present a DNA tile–driven in vivo logical encoding self-assembly (TILES) strategy for robust and signal-amplified imaging of multiple biomarkers in cancer cells and tumor-bearing mice. Capitalizing on AND-gated logic operations, the TILES assay enables confined recognition of dual biomarkers to initiate the intracellular self-assembly of DNA scaffolds, yielding nanotube-like signals. Owing to the compact nucleic acid framework, DNA scaffolds exhibit an over sevenfold nuclease resistance enhancement than double-stranded DNA probes. Moreover, the structural output, characterized by high-density fluorophore architecture and defined morphology, substantially boosts the visualization and precise classification of diverse cancer types. The proposed strategy provides a robust platform to enable the high-fidelity, multiplexed profiling of intracellular biomarkers and dynamic gene regulatory networks analysis in living organisms.
- 19 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13279-13301
Smart Wearable Sensor Fuels Noninvasive Body Fluid Analysis
The advancements in wearable sensor technology have revolutionized noninvasive body fluid monitoring, offering new possibilities for continuous and real-time health assessment. By analyzing body fluids such as sweat, saliva, tears, and interstitial fluid, these technologies provide painless diagnostic alternatives for detecting biomarkers such as glucose, electrolytes, and metabolites. These sensors play a crucial role in early disease detection, chronic condition management, and personalized healthcare. Recent innovations in flexible electronics, microfluidic systems, and biosensing materials have significantly improved the accuracy, reliability, and integration of sensors into everyday textiles. Moreover, the convergence of artificial intelligence and big data analytics has enhanced the precision and personalization of health monitoring systems, transforming wearable sensors into powerful tools for health holographic inspection. Despite significant progress, challenges remain, including improving sensor stability in dynamic environments, achieving real-time data transmission, and covering a broader range of biomarkers. Future research directions focus on enhancing material sustainability through green synthesis, optimizing sampling techniques, and leveraging machine learning to further improve sensor performance. This Review highlights the transformative potential of wearable sensors in medical applications, aiming to bridge gaps in healthcare accessibility and elevate the standards of patient care through noninvasive continuous monitoring technologies.
- 19 February 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (9) , 13279-13301
Smart Wearable Sensor Fuels Noninvasive Body Fluid Analysis
The advancements in wearable sensor technology have revolutionized noninvasive body fluid monitoring, offering new possibilities for continuous and real-time health assessment. By analyzing body fluids such as sweat, saliva, tears, and interstitial fluid, these technologies provide painless diagnostic alternatives for detecting biomarkers such as glucose, electrolytes, and metabolites. These sensors play a crucial role in early disease detection, chronic condition management, and personalized healthcare. Recent innovations in flexible electronics, microfluidic systems, and biosensing materials have significantly improved the accuracy, reliability, and integration of sensors into everyday textiles. Moreover, the convergence of artificial intelligence and big data analytics has enhanced the precision and personalization of health monitoring systems, transforming wearable sensors into powerful tools for health holographic inspection. Despite significant progress, challenges remain, including improving sensor stability in dynamic environments, achieving real-time data transmission, and covering a broader range of biomarkers. Future research directions focus on enhancing material sustainability through green synthesis, optimizing sampling techniques, and leveraging machine learning to further improve sensor performance. This Review highlights the transformative potential of wearable sensors in medical applications, aiming to bridge gaps in healthcare accessibility and elevate the standards of patient care through noninvasive continuous monitoring technologies.
- Open Access
- 2 November 2024
- Published by Elsevier in Alexandria Engineering Journal
- Vol. 112, 84-97
An improved lightweight ConvNeXt for rice classification
- 2 November 2024
- Published by Elsevier in Alexandria Engineering Journal
- Vol. 112, 84-97
Open AccessAn improved lightweight ConvNeXt for rice classification
- 21 November 2023
- Published by Wiley in BioFactors
- Vol. 50 (3) , 408-421
Pax‐8: Molecular biology, pathophysiology, and potential pathogenesis
Transcription factors, as the convergence points of multiple signaling pathways in eukaryotic cells, are closely involved in disease development. Pax‐8, an important transcription factor belonging to the Pax family, exerts a crucial influence on the regulation of gene expression required for both physiological conditions and pathological processes. Pax‐8 contributes to the pathogenesis of many human diseases, ranging from cardiovascular disease to many cancers, and therefore, it can be imagined that Pax‐8 holds great therapeutic potential. In this review, we summarize the structure, distribution, function, and regulatory mechanisms of Pax‐8 to provide a new research direction for Pax‐8.
- 21 November 2023
- Published by Wiley in BioFactors
- Vol. 50 (3) , 408-421
Pax‐8: Molecular biology, pathophysiology, and potential pathogenesis
Transcription factors, as the convergence points of multiple signaling pathways in eukaryotic cells, are closely involved in disease development. Pax‐8, an important transcription factor belonging to the Pax family, exerts a crucial influence on the regulation of gene expression required for both physiological conditions and pathological processes. Pax‐8 contributes to the pathogenesis of many human diseases, ranging from cardiovascular disease to many cancers, and therefore, it can be imagined that Pax‐8 holds great therapeutic potential. In this review, we summarize the structure, distribution, function, and regulatory mechanisms of Pax‐8 to provide a new research direction for Pax‐8.
- 10 February 2023
- Published by Elsevier in Biomaterials
- Vol. 295, 121994
Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity
- 10 February 2023
- Published by Elsevier in Biomaterials
- Vol. 295, 121994
Molecular superglue-mediated higher-order assembly of TRAIL variants with superior apoptosis induction and antitumor activity
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5100
Abstract 5100: Analysis of genetic alterations related to hyper-progressive disease after immunotherapy in patients with non-small cell lung cancer
Background Hyper-progressive disease (HPD) is an unexpected response pattern observed in immune checkpoint therapy, such patients experience a very rapid disease progression (usually progressed seriously in three months). Predictors of HPD are one of the keys to the management of patients receiving immune checkpoint inhibitors. Some factors, such as MDM2/4 amplification, EGFR mutations and old age may be risk factors for HPD, but the results of different studies are inconsistent. Herein, we evaluated the characteristics of MDM2/4 alterations in Chinese patients with NSCLC. Methods The formalin-fixed paraffin-embedded specimens of cancer patients who have underwent next-generation sequencing (NGS) in 3D Medicines, a laboratory accredited by CAP and Clinical Laboratory Improvement Amendments (CLIA) from May 2017 to May 2020, were included in this study. NGS was performed to detect gene mutation, and tumor mutational burden (TMB) measured by a 733 gene panel. PD-L1 expression detected by using Dako PD-L1 IHC 22C3 pharmDx. Results The proportion of MDM2/4 amplification in Chinese NSCLC patients is 0.86%, the proportion of MDM2 and MDM4 amplification in Chinese NSCLC patients were 0.74% and 0.12%. respectively. Further analysis found lower TMB level in patients with MDM2/4 amplification than patients without MDM2/4 amplification (pCitation Format: Xudong Xiang, Hushan Zhang, Deguang Wang, Heng Li, Qing Lei, Qianli Ma. Analysis of genetic alterations related to hyper-progressive disease after immunotherapy in patients with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5100.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 5100
Open AccessAbstract 5100: Analysis of genetic alterations related to hyper-progressive disease after immunotherapy in patients with non-small cell lung cancer
Background Hyper-progressive disease (HPD) is an unexpected response pattern observed in immune checkpoint therapy, such patients experience a very rapid disease progression (usually progressed seriously in three months). Predictors of HPD are one of the keys to the management of patients receiving immune checkpoint inhibitors. Some factors, such as MDM2/4 amplification, EGFR mutations and old age may be risk factors for HPD, but the results of different studies are inconsistent. Herein, we evaluated the characteristics of MDM2/4 alterations in Chinese patients with NSCLC. Methods The formalin-fixed paraffin-embedded specimens of cancer patients who have underwent next-generation sequencing (NGS) in 3D Medicines, a laboratory accredited by CAP and Clinical Laboratory Improvement Amendments (CLIA) from May 2017 to May 2020, were included in this study. NGS was performed to detect gene mutation, and tumor mutational burden (TMB) measured by a 733 gene panel. PD-L1 expression detected by using Dako PD-L1 IHC 22C3 pharmDx. Results The proportion of MDM2/4 amplification in Chinese NSCLC patients is 0.86%, the proportion of MDM2 and MDM4 amplification in Chinese NSCLC patients were 0.74% and 0.12%. respectively. Further analysis found lower TMB level in patients with MDM2/4 amplification than patients without MDM2/4 amplification (pCitation Format: Xudong Xiang, Hushan Zhang, Deguang Wang, Heng Li, Qing Lei, Qianli Ma. Analysis of genetic alterations related to hyper-progressive disease after immunotherapy in patients with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5100.
- RetractionOpen Access
- 14 February 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (4) , 1
[Retracted] Long non‑coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA‑212‑3p expression
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the Transwell cell migration assay data shown in Figs. 5C and D, and 7A and B, were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to Experimental and Therapeutic Medicine, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Experimental and Therapeutic Medicine 16: 779-787, 2018; DOI: 10.3892/etm.2018.6216]
- 14 February 2022
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 23 (4) , 1
RetractionOpen Access[Retracted] Long non‑coding RNA TUG1 promotes osteosarcoma cell proliferation and invasion through inhibition of microRNA‑212‑3p expression
Following the publication of this paper, it was drawn to the Editors' attention by a concerned reader that the Transwell cell migration assay data shown in Figs. 5C and D, and 7A and B, were strikingly similar to data appearing in different form in other articles by different authors. Owing to the fact that the contentious data in the above article had already been published elsewhere, or were already under consideration for publication, prior to its submission to Experimental and Therapeutic Medicine, the Editor has decided that this paper should be retracted from the Journal. The authors were asked for an explanation to account for these concerns, but the Editorial Office did not receive any reply. The Editor apologizes to the readership for any inconvenience caused. [the original article was published in Experimental and Therapeutic Medicine 16: 779-787, 2018; DOI: 10.3892/etm.2018.6216]
- 4 December 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (6) , 4216-4230
Zinc finger E‐box binding homeobox 1 and atherosclerosis: New insights and therapeutic potential
Zinc finger E‐box binding homeobox 1 (ZEB1), an important transcription factor belonging to the ZEB family, plays a crucial role in regulating gene expression required for both normal physiological and pathological processes. Accumulating evidence has shown that ZEB1 participates in the initiation and progression of atherosclerotic cardiovascular disease. Recent studies suggest that ZEB1 protects against atherosclerosis by regulation of endothelial cell angiogenesis, endothelial dysfunction, monocyte‐endothelial cell interaction, macrophage lipid accumulation, macrophage polarization, monocyte‐vascular smooth muscle cell (VSMC) interaction, VSMC proliferation and migration, and T cell proliferation. In this review, we summarize the recent progress of ZEB1 in the pathogenesis of atherosclerosis and provide insights into the prevention and treatment of atherosclerotic cardiovascular disease.
- 4 December 2020
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (6) , 4216-4230
Zinc finger E‐box binding homeobox 1 and atherosclerosis: New insights and therapeutic potential
Zinc finger E‐box binding homeobox 1 (ZEB1), an important transcription factor belonging to the ZEB family, plays a crucial role in regulating gene expression required for both normal physiological and pathological processes. Accumulating evidence has shown that ZEB1 participates in the initiation and progression of atherosclerotic cardiovascular disease. Recent studies suggest that ZEB1 protects against atherosclerosis by regulation of endothelial cell angiogenesis, endothelial dysfunction, monocyte‐endothelial cell interaction, macrophage lipid accumulation, macrophage polarization, monocyte‐vascular smooth muscle cell (VSMC) interaction, VSMC proliferation and migration, and T cell proliferation. In this review, we summarize the recent progress of ZEB1 in the pathogenesis of atherosclerosis and provide insights into the prevention and treatment of atherosclerotic cardiovascular disease.
- 1 April 2020
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 192, 110267
Endosulfan promotes cell migration via PTP4A3-mediated signaling pathways in HUVECs
- 1 April 2020
- Published by Elsevier in Ecotoxicology and Environmental Safety
- Vol. 192, 110267
Endosulfan promotes cell migration via PTP4A3-mediated signaling pathways in HUVECs